HIMS:NYSEHims & Hers Health, Inc. Analysis
Data as of 2026-04-08 - not real-time
$19.50
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Hims & Hers Health (HIMS) trades around $19.5, notably above its DCF‑derived fair value of roughly $15.5 and a PE of 39.8× versus the industry average of 25.8×, indicating the stock is currently overvalued. Technical indicators are mixed: the 20‑day SMA (≈22) sits above price, the MACD histogram is negative and volume is trending down, suggesting short‑term pressure, while the 50‑day SMA still provides modest support.
The company delivers robust top‑line growth (≈28% YoY) and solid gross margins (≈74%), yet carries a high debt‑to‑equity ratio (>200%) and faces a fresh regulatory probe in Louisiana plus tariff concerns for a key drug partnership. Recent analyst upgrades and a renewed Novo Nordisk collaboration have lifted sentiment, but the combination of elevated beta (≈2.3), extreme 30‑day volatility (>130%) and the regulatory cloud keeps risk levels elevated.
The company delivers robust top‑line growth (≈28% YoY) and solid gross margins (≈74%), yet carries a high debt‑to‑equity ratio (>200%) and faces a fresh regulatory probe in Louisiana plus tariff concerns for a key drug partnership. Recent analyst upgrades and a renewed Novo Nordisk collaboration have lifted sentiment, but the combination of elevated beta (≈2.3), extreme 30‑day volatility (>130%) and the regulatory cloud keeps risk levels elevated.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD and decreasing volume
- Current price above fair value
- Regulatory investigation adds downside risk
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Forward PE compression to ~12× suggests upside if earnings accelerate
- Renewed partnership with Novo Nordisk drives growth expectations
- Regulatory and tariff uncertainties remain unresolved
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Sustained revenue growth and high gross margins
- High leverage and overvaluation limit upside
- Diversified market presence mitigates geographic concentration
Key Metrics & Analysis
Financial Health
Revenue Growth28.40%
Profit Margin5.47%
P/E Ratio39.8
ROE25.23%
ROA5.29%
Debt/Equity207.16
P/B Ratio8.2
Op. Cash Flow$300.0M
Free Cash Flow$110.5M
Industry P/E25.8
Technical Analysis
TrendNeutral
RSI45.1
Support$18.62
Resistance$27.54
MA 20$22.02
MA 50$20.74
MA 200$39.38
MACDBearish
VolumeDecreasing
Fear & Greed Index85.2
Valuation
Fair Value$15.49
Target Price$24.15
Upside/Downside23.87%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta1.94
Volatility134.36%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.